Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MT-303 + atezolizumab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Myeloid Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
MT-303 + atezolizumab + bevacizumab is a combination therapy being developed by Myeloid Therapeutics for the treatment of advanced or metastatic GPC3-expressing hepatocellular carcinoma (HCC). MT-303 is a first-in-class, in vivo mRNA chimeric antigen receptor (CAR) therapy encapsulated in lipid nanoparticles (LNPs). It is designed to program myeloid cells to recognize and destroy Glypican-3 (GPC3)-expressing tumor cells following intravenous administration. Atezolizumab is a monoclonal antibody that acts as a PD-L1 inhibitor, while bevacizumab is a monoclonal antibody that targets VEGF to inhibit angiogenesis. This combination approach aims to leverage the direct tumor-targeting capabilities of in vivo CAR-programmed myeloid cells alongside established immune checkpoint inhibition and anti-angiogenic therapy to improve outcomes in HCC patients.
- Other names
- MT-303 in combination with atezolizumab and bevacizumabMT303 in combination with atezolizumab and bevacizumabMT 303 in combination with atezolizumab and bevacizumabMT-303 in combination with Atezo/Bev
02
Targets
VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)GPC3 (Glypican-3)
Beyond the preview
Go deeper on MT-303 + atezolizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MT-303 + atezolizumab + bevacizumab.